Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia
Geron announced oral and poster presentations of imetelstat (RYTELO) data in lower-risk MDS at hematology congresses in Japan and the German-Austrian-Swiss region. The data include a real-world U.S. claims cohort of 58 patients — most initiating in third line or later — showing ~67% remained on therapy at 6 months, plus durable transfusion independence in Korean patients from IMerge. Presentations also integrate IMerge molecular findings, suggesting early transient cytopenias may be an on-target effect predictive of better response.
Key figures
- Drug Name
- RYTELO (imetelstat)
- Phase Of Trial
- Phase 3
- Korean patients n
- 13
- Retention 6 months
- ~67% (KM estimate)
- Real world cohort n
- 58
- Mean age at diagnosis
- 75
- Third line or later initiation
- 71%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.